Schneider National, Inc. announces participation in upcoming conference

GREEN BAY, Wis.--(BUSINESS WIRE)-- Schneider National, Inc. (NYSE: SNDR), a premier multimodal provider of transportation, intermodal and logistics services, today announced participation in the following investment conference:

• 2026 Morgan Stanley 14th Annual Laguna Conference: Tuesday, September 15, 2026. Jim Filter, President and Chief Executive Officer, and Darrell Campbell, Executive Vice President and Chief Financial Officer, will participate in a fireside chat and a series of investor discussions. The chat will begin at 4:05 p.m. (Pacific Time) / 6:05 p.m. (Central Time).

A webcast for this event may be located on Schneider’s Investor Relations website (www.investors.schneider.com) and available for a limited time following the conference.

About Schneider

Schneider is a premier multimodal provider of transportation, intermodal and logistics services, helping customers turn supply chain complexity into greater control. Backed by more than 90 years of operational expertise and innovation, Schneider delivers reliable, flexible and responsible solutions that help businesses move freight with confidence.

Schneider’s broad portfolio includes Regional and Long-Haul, Truckload, Expedited, Dedicated, Bulk, Intermodal, Brokerage, Warehousing, Supply Chain Management, Port Logistics and Logistics Consulting. Through its digital marketplace, Schneider FreightPower®, the company gives shippers access to an expanded, highly flexible capacity network and carriers access to quality drop-and-hook freight.

For more information about Schneider, visit Schneider.com or follow the company socially on Facebook, LinkedIn and X: @WeAreSchneider. Always Delivering. Always Ahead.

Source: Schneider SNDR

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831996391/en/

For additional or story assistance, please contact
Kara Leiterman, Media Relations Manager
920-357-2867

Source: Schneider SNDR

You May Also Be Interested In

• Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
• KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
• BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy